Drug Utilisation of Mysimba/Contrave

Primary outcomes

1. Demographic characteristics of patients initiating use of Mysimba/Contrave (Age)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   Patient demographics (years of age on index date)

2. Demographic characteristics of patients initiating use of Mysimba/Contrave (Sex)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   Patient demographics (sex [male/female] on index date)

3. Demographic characteristics of patients initiating use of Mysimba/Contrave (Race)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   Clinically recorded race (i.e., White, Black or African American, Asian, or other/unknown) and ethnicity (i.e., Hispanic or Latino, Non-Hispanic or Latino, or unknown)

4. Demographic characteristics of patients initiating use of Mysimba/Contrave (Smoking Status)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   Smoking status (i.e., current or ever)

5. Demographic characteristics of patients initiating use of Mysimba/Contrave (Comorbidities)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   Existing comorbidities:

   • Metabolic comorbidities (i.e., diabetes or dyslipidemia);
   • Hypertension;
   • Seizure disorder;
   • Hepatic impairment;
   • Central nervous system tumor

6. Demographic characteristics of patients initiating use of Mysimba/Contrave (Substance Abuse/Dependencies)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   History of substance abuse/dependencies; including acute opioid withdrawal

7. Demographic characteristics of patients initiating use of Mysimba/Contrave (Medical Conditions)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   History of the following medical conditions:

   • Seizures;
   • Bipolar disorder;
   • Major depressive disorder (MDD);
   • Anorexia nervosa;
   • Bulimia;
   • Prior use of naltrexone, bupropion, opioid, or MAOI

8. Demographic characteristics of patients initiating use of Mysimba/Contrave (Pregnancy)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   Pregnancy status.

9. Demographic characteristics of patients initiating use of Mysimba/Contrave (Breastfeeding)

   Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

   Breastfeeding status.

10. Patterns of Mysimba/Contrave initiation (Rx)

    Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

    Mysimba/Contrave initiation includes number of prescriptions

11. Patterns of Mysimba/Contrave initiation (Episodes)

    Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

    Mysimba/Contrave initiation includes number of treatment episodes

12. Patterns of Mysimba/Contrave initiation (Duration)

    Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

    Mysimba/Contrave initiation includes duration between prescriptions

13. Baseline characteristics of patients initiating use of Mysimba/Contrave (Height)

    Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

    Height (meters) (most recent value on or before the index date)

14. Baseline characteristics of patients initiating use of Mysimba/Contrave (Weight)

    Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

    Weight (kg) (most recent value on or before the index date)

15. Baseline characteristics of patients initiating use of Mysimba/Contrave (BMI)

    Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

    BMI (kg/m2) (most recent value on or before the index date) (obtained directly from data sources; BMI may be calculated if height and weight available)

16. Patterns of Mysimba/Contrave use (Compliance)

    Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

    Mysimba/Contrave use includes the number and percentage of patients compliant with the SmPC.

17. Patterns of Mysimba/Contrave use (Non-compliance)

    Time frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

    Mysimba/Contrave use includes the number and percentage of patients non-compliant with the SmPC.